π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #15 πŸ“’

Outside-In: Why Putting Patients at the Heart of Drug Development Matters

πŸ“„ This article outlines the necessity of adopting a patient-centric approach in drug development to benefit patients and enhance the success of new medicines. The authors underscore the critical importance of integrating patient perspectives from the outset. Traditional drug development has typically followed an inside-out approach, starting with the molecule and eventually considering patient needs. However, a paradigm shift to an outside-in, patient-centric model is advocated. This model begins by understanding patient needs and disease areas with unmet medical needs, then develops molecules tailored to these needs.

πŸ•°οΈ When should the patient view be incorporated?
Incorporating patient views early, ideally when a molecule enters the clinical stage, is crucial. Engaging patients and focus groups during Phase I can refine the target product profile and capture patient-reported outcomes. As development progresses, consolidating patient associations and disease awareness campaigns becomes vital, especially during Phase III trials. Post-approval, ongoing patient education, and monitoring are essential to address side effects and gather real-world feedback, ensuring continuous improvement and safety.

πŸ“ Where is it important to incorporate the patient's view?
Particularly in chronic conditions like diabetic neuropathic pain, fibromyalgia, and cancer-associated pain, a patient-centric approach is indispensable. Understanding patient experiences and clustering patients based on specific characteristics can significantly enhance study design and treatment efficacy. Input from clinicians and patient advocates is also valuable in regulatory discussions, balancing immediate regulatory requirements with potential future needs.

🀝 How do we engage with patients?
Engaging deeply with patients involves listening to their experiences, understanding their quality of life, and addressing comorbidities. This detailed understanding aids in developing personalized treatments for different patient subgroups. Challenges in patient enrollment and retention, especially in complex and chronic conditions, further highlight the need for a patient-centric focus.

πŸ” In conclusion, the biopharma industry must systematically integrate patient perspectives at all stages of drug development. This approach not only improves transparency and trust but also ensures that new medicines meet the true needs of patients, fostering better healthcare outcomes.

πŸ“š Reference:
Cole, L., Merante, D., Outside-In: Why Putting Patients at the Heart of Drug Development Matters. Applied Clinical Trials 2018.

Previous
Previous

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #16 πŸ“’

Next
Next

π—ͺπ—²π—²π—Έπ—Ήπ˜† π—¦π—½π—Όπ˜π—Ήπ—Άπ—΄π—΅π˜ #14 πŸ“’